---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-22-014407"
form_type: "8-K/A"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2022-08-24T23:59:59+00:00"
generated_at: "2026-06-23T21:39:28.591677+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precigen completes $170M sale of Trans Ova Genetics; pro forma shows $213M cash

## Summary
- Closed sale of 100% of Trans Ova to Spring Bidco LLC for $170M; net cash proceeds ~$169.5M.
- Pro forma cash and equivalents rise to $213.4M from $43.8M as of June 30, 2022.
- Pro forma continuing ops loss of $49.2M for H1 2022 vs. historical loss of $36.9M (net of discontinued ops).
- Pro forma continuing ops loss of $110.8M for FY2021, compared to historical net loss of $96.8M.
- Pro forma balance sheet eliminates $88.9M of assets and $15.1M of liabilities classified as held for sale.

## SEC filing metadata
- accession: 0000950103-22-014407
- form_type: 8-K/A
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2022-08-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010322014407/0000950103-22-014407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010322014407/dp178970_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-22-014407
- JSON: https://secwatch.observer/filing/0000950103-22-014407.json
- Plain text: https://secwatch.observer/filing/0000950103-22-014407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.